Synaptogenix, Inc., an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, commented on the positive Phase 3 trial results for Lecanemab announced last...
Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis ("MS"),...
